Despite recent marked therapeutic advances made in clear cell Renal Cell Carcinoma (ccRCC), there remains no standard of care for kidney cancer of non-clear cell histology (nccRCC).
1
In the current issue of Clinical Genitourinary Cancer, three articles were chosen to highlight the efficacy of immunotherapy on ccRCC and nccRCC.2
, 3
, 4
In the article “Safety and Efficacy of Nivolumab in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma: Results From the Phase IIIb/IV CheckMate 374 Study” where 44 nccRCC patients were treated with nivolumab 240mg Q2W, Vogelzang et al. reported responses in several histologies.2
In the article “Clinical activity of ipilimumab plus nivolumab in patients with metastatic non-clear cell renal cell carcinoma” where 18 nccRCC patients were treated with Ipilimumab and nivolumab, Gupta et al. reported objective responses and notable toxicity in patients with nccRCC.3
In the companion Checkmate 374 ccRCC paper “Safety and Efficacy of Nivolumab in Patients With Advanced Clear Cell Renal Cell Carcinoma: Results From the Phase IIIb/IV CheckMate 374 Study”, McFarlane et al. validated the safety and efficacy of nivolumab for previously treated advanced ccRCC.4
Prostate Cancer
In the article “Phase 2 Trial Of Gtx-758, And Estrogen Receptor Alpha Agonist, In Men With Castration-Resistant Prostate Cancer”, Yu et al. assessed the ability of GTx-758, an oral selective estrogen receptor alpha agonist, to result in a ≥ 50% PSA decline by day 90, and demonstrated its dose-dependent clinical activity.
5
In the article “Long-Term Castration-Related Outcomes In Patients With High-Risk Localized Prostate Cancer Treated With Androgen Deprivation Therapy With Or Without Docetaxel And Estramustine In The UNICANCER GETUG-12 Trial”, Dumont et al. explored whether the addition of DE impacts long-term treatment-related side effects in the GETUG-12 phase III trial, and reported that treatment with DE was not associated with excess long-term castration-related toxicity in men with high-risk localized prostate cancer.
6
In the article “A Nationwide Persistent Underutilization Of Adjuvant Radiotherapy In North American Prostate Cancer Patients” Rakic et al. identified 189,240 prostate cancer patients with adverse features at prostatectomy (positive margin, stage ≥pT3a, and/or pN1 disease) from 2004-2015; and reported a a significant underutilization of aRT in eligible patients with prostate cancer.
7
Bladder Cancer
In the article “Final Overall Survival Analysis Of The SOGUG Phase II MAJA Study: Maintenance Vinflunine Versus Best Supportive Care After First-Line Chemotherapy In Advanced Urothelial Carcinoma” Bellmunt et al. reported their Final analysis in support of VFL in maintenance therapy in patients with disease control after first-line treatment with CG, with no unexpected long-term adverse effects.
8
Kidney Cancer
In the article “Correlation Between Immuno-Related Adverse Events (iRAE) Occurrence And Clinical Outcome In Metastatic Renal Cell Carcinoma (mRCC) Patients Treated With Nivolumab: IRAENE Trial, An Italian Multi-Institutional Retrospective Study” Vitale et al. reported their retrospective analysis of 167 mRCC patients treated with nivolumab and reported the association of irAEs with better clinical outcomes.
9
- Vitale M.G.
- Pipitone S.
- Venturelli M.
- et al.
Correlation between immune-related adverse event (IRAE) occurrence and clinical outcome in patients with metastatic renal cell carcinoma (mRCC) treated with nivolumab: IRAENE trial, an Italian Multi-institutional Retrospective Study.
Clin Genitourin Cancer. 2020; 18: 477-488
In the article “Chronic Kidney Disease After Partial Nephrectomy In Patients With Preoperative Inconspicuous Renal Function - Curiosity Or Relevant Issue?” Nientiedt et al. reported that every fifth patient with normal preoperative renal function developed CKD, and elderly patients with higher tumor stage and who require blood transfusion appear to be at increased risk.
10
Rare GU Cancer
In this review article “TFE3 Gene Rearrangement in Perivascular Epithelioid Cell Neoplasm (PEComa) of the genitourinary tract” Vannucchi et al. discussed common (TSC genes mutated) and rare (TFE3 rearranged) PEComas in GU cancers.
11
Biomarker
In the article “Myeloid Derived Suppressor Cells (MDSC) In Non-Metastatic Urothelial Carcinoma Of Bladder Is Associated With Pathologic Complete Response (Pcr) And Overall Survival” Fallah et al. tested their hypothesis that lower blood MDSC would correlate with pathologic complete response and better outcomes in nonmetastatic urothelial carcinoma (UC); and higher WB M-MDSC and UnC-MDSC before cystectomy had negative prognostic value.
12
In the article” PD-L1 Assay Concordance in Metastatic Renal Cell Carcinoma and Metastatic Urothelial Carcinoma” Brown et al. compared Dako 28-8 and Ventana SP142 PD-L1 immunohistochemistry assays in mRCC, and Dako 22C3 and Ventana SP263 in mUC; and reported strong concordance between PD-L1 assays chosen for comparison in both mRCC and mUC.
13
References
- The therapeutic landscape of renal cell carcinoma: From the dark age to the golden age.Semin Nephrol. 2020; 40: 28-41
- Safety and efficacy of nivolumab in patients with advanced non–clear cell renal cell carcinoma: Results from the phase IIIb/IV checkmate 374 study.Clin Genitourin Cancer. 2020; 18: 461-468
- Clinical activity of ipilimumab plus nivolumab in patients with metastatic non–clear cell renal cell carcinoma.Clin Genitourin Cancer. 2020; 18: 429-435
- Safety and efficacy of nivolumab in patients with advanced clear cell renal cell carcinoma: Results from the phase IIIb/IV checkmate 374 study.Clin Genitourin Cancer. 2020; 18: 469-476
- Phase 2 trial of GTx-758, an estrogen receptor alpha agonist, in men with castration-resistant prostate cancer.Clin Genitourin Cancer. 2020; 18: 436-443
- Long-term castration-related outcomes in patients with high-risk localized prostate cancer treated with androgen deprivation therapy with or without docetaxel and estramustine in the UNICANCER GETUG-12 trial.Clin Genitourin Cancer. 2020; 18: 444-451
- A nationwide persistent underutilization of adjuvant radiotherapy in north american prostate cancer patients.Clin Genitourin Cancer. 2020; 18: 489-499
- Final overall survival analysis of the SOGUG Phase 2 MAJA study: Maintenance vinflunine versus best supportive care after first-line chemotherapy in advanced urothelial carcinoma.Clin Genitourin Cancer. 2020; 18: 452-460
- Correlation between immune-related adverse event (IRAE) occurrence and clinical outcome in patients with metastatic renal cell carcinoma (mRCC) treated with nivolumab: IRAENE trial, an Italian Multi-institutional Retrospective Study.Clin Genitourin Cancer. 2020; 18: 477-488
- Chronic kidney disease after partial nephrectomy in patients with preoperative inconspicuous renal function – curiosity or relevant issue?.Clin Genitourin Cancer. 2020; 18: e754-e761
- TFE3 gene rearrangement in perivascular epithelioid cell neoplasm (PEComa) of the genitourinary tract.Clin Genitourin Cancer. 2020; 18: e692-e697
- Myeloid-derived suppressor cells in nonmetastatic urothelial carcinoma of bladder is associated with pathologic complete response and overall survival.Clin Genitourin Cancer. 2020; 18: 500-508
- PD-L1 assay concordance in metastatic renal cell carcinoma and metastatic urothelial carcinoma.Clin Genitourin Cancer. 2020; 18: 509-513
Article info
Identification
Copyright
© 2020 Published by Elsevier Inc.
